Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

KTTA

Pasithea Therapeutics Corp

Apr 18 • 04:00PM ET

7.15

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-13.31	Insider Own	28.46%	Shs Outstand	1.04M	Perf Week	-6.54%
Market Cap	7.44M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	0.75M	Perf Month	0.49%
Income	-15.96M	PEG	-	EPS next Q	-	Inst Own	1.19%	Short Float	1.16%	Perf Quarter	-2.29%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	1.65	Perf Half Y	-15.80%
Book/sh	22.46	P/B	0.32	EPS next Y	-	ROA	-43.50%	Short Interest	0.01M	Perf Year	-6.39%
Cash/sh	15.70	P/C	0.46	EPS next 5Y	-	ROE	-47.07%	52W Range	5.25 - 17.40	Perf YTD	-3.38%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-68.22%	52W High	-58.91%	Beta	0.84
Dividend TTM	-	Quick Ratio	6.34	Sales past 5Y	-33.33%	Gross Margin	-	52W Low	36.09%	ATR (14)	0.39
Dividend Ex-Date	-	Current Ratio	6.34	EPS Y/Y TTM	-20.79%	Oper. Margin	0.00%	RSI (14)	44.55	Volatility	2.72% 4.05%
Employees	8	Debt/Eq	0.00	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	40.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-23.32%	Payout	-	Rel Volume	0.13	Prev Close	7.15
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-100.00%	Earnings	-	Avg Volume	5.27K	Price	7.15
SMA20	-4.89%	SMA50	-1.26%	SMA200	-15.61%	Trades		Volume	702	Change	0.00%

Apr-15-24 11:00AM	11 Undervalued Stocks for Less Than $50 in April 2024 (Investopedia)
Feb-13-24 07:59AM	Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004 (GlobeNewswire) +8.95%
Jan-08-24 07:59AM	Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position (GlobeNewswire) +5.03%
Jan-02-24 08:35AM	Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients (GlobeNewswire) +8.78%
Dec-28-23 05:00PM	Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023 (GlobeNewswire)
05:19PM	Loading…
Dec-19-23 05:19PM	Pasithea Therapeutics Announces Results from 2023 Annual Meeting (GlobeNewswire) -6.06%
Dec-13-23 09:03AM	Why Is Pasithea Therapeutics (KTTA) Stock Down 12% Today? (InvestorPlace)
Dec-11-23 11:18AM	Why Is Pasithea Therapeutics (KTTA) Stock Up 105% Today? (InvestorPlace) +47.42%
08:01AM	Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models (GlobeNewswire)
Nov-29-23 04:27PM	Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders (GlobeNewswire) +6.63%
07:59AM	Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development (GlobeNewswire)
Nov-09-23 07:59AM	Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets 5 1 Integrin for the Treatment of both Sporadic and Familial ALS (GlobeNewswire)
Sep-14-23 08:30AM	Pasithea Therapeutics Corp. Announces Final Results of Tender Offer (GlobeNewswire)
Sep-07-23 04:14PM	Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-01-23 07:59AM	Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in 5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting 5 integrin results in improved survival and motor function (GlobeNewswire)
06:00AM	Loading…
Jul-31-23 06:00AM	The Psychedelics Stock Universe Is Shrinking, Despite the Hype (Bloomberg)
Jul-20-23 08:43AM	Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash (GlobeNewswire) +25.88%
08:40AM	Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc. (GlobeNewswire)
Jul-13-23 09:14AM	Lucy Scientific Scores Richard Nanula as CEO After Senior Roles at Disney, Amgen, Starwood (Exec Edge)
Jun-30-23 09:28AM	Pasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of Directors (GlobeNewswire)
Jun-29-23 02:50PM	Lucy Scientific Discovery Reiterates Its Proposal to Acquire Pasithea Therapeutics Corp. (GlobeNewswire) +11.24%
08:29AM	Pasithea Therapeutics Announces Completion of GMP Manufacturing for PAS-004 (GlobeNewswire)
Jun-06-23 04:30PM	Pasithea Therapeutics Confirms Receipt of Unsolicited Proposal from Lucy Scientific Discovery Inc. (GlobeNewswire)
Jun-05-23 09:00AM	Lucy Scientific Discovery Announces Proposal to Acquire Pasithea Therapeutics Corp. (GlobeNewswire) +25.00%
Jun-01-23 07:57AM	Pasithea Therapeutics Abstract Accepted for Poster Presentation at 2023 Neurofibromatosis Conference (GlobeNewswire)
May-14-23 08:13AM	Pasithea Therapeutics First Quarter 2023 Earnings: US$0.13 loss per share (vs US$0.068 loss in 1Q 2022) (Simply Wall St.)
May-03-23 08:26AM	Pasithea Therapeutics to Participate in EF Hutton Inaugural Global Conference (GlobeNewswire)
Mar-02-23 08:00AM	Pasithea Therapeutics Chairman, Prof. Lawrence Steinman, to Deliver Keynote Address at the American Association for Advancement of Science (AAAS) Annual Meeting (GlobeNewswire)
Feb-23-23 08:00AM	Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P. Johnson Lecture at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) (GlobeNewswire) -5.64%
Feb-16-23 07:30AM	Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Receive Pioneer in Medicine Award (GlobeNewswire)
08:00AM	Loading…
Jan-18-23 08:00AM	Pasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004 (GlobeNewswire)
Dec-14-22 05:18PM	Majority of Stockholders Support Pasithea Directors at Special Meeting (GlobeNewswire)
Dec-12-22 07:00AM	Pasithea Therapeutics Announces Comprehensive Settlement Agreement with the Camac Group (GlobeNewswire) -8.22%
Dec-07-22 04:00PM	Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics (Business Wire)
Dec-06-22 08:00AM	Pasithea Therapeutics to Present at Annual Meeting of the Antibody Society Conference (GlobeNewswire)
Nov-28-22 07:05PM	Pasithea Therapeutics Postpones Special Meeting until December 9, 2022 at 9:00 AM Eastern Time (GlobeNewswire)
Nov-22-22 04:00PM	Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics (Business Wire)
Oct-27-22 09:50AM	A New BioTech Research Race Is Focused On Improving Life For MS Patients (News Direct)
Oct-17-22 08:00AM	Pasithea Therapeutics to Present Tolerizing Vaccine Program Results at Immunotherapy 2022 International Course and Symposium (GlobeNewswire) -11.20%
Oct-14-22 09:48AM	Pasithea' Largest Investor Group Says AlloMek Therapeutics Deal Ill-timed, Highly Dilutive (Benzinga)
Oct-13-22 04:00PM	Investor Group Comments on Pasithea Therapeutics Seemingly Defensive and Ill-Timed Acquisition of AlloMek Therapeutics (Business Wire)
Oct-12-22 08:00AM	Pasithea Therapeutics Acquires AlloMek Therapeutics (GlobeNewswire)
07:31AM	EXCLUSIVE: Pasithea Bolsters CNS-Focused Pipeline With AlloMek Therapeutics Acquisition (Benzinga)
Oct-10-22 09:39AM	New Drugs And Therapies Are Giving MS And ALS Sufferers New Hope (News Direct)
Oct-03-22 06:03PM	Pasithea Therapeutics to Call Special Meeting of Stockholders (GlobeNewswire)
09:09AM	Biotech Company Pleased With Results Of Early Testing Demonstrating Vaccine Potential For Multiple Sclerosis (News Direct)
Sep-28-22 09:00AM	Investor Group Sends Letter to Pasithea Therapeutics Board of Directors (Business Wire)
Sep-20-22 08:00AM	Pasithea Therapeutics Appoints Life Sciences and Health Care Executive Alfred J. Novak to its Board of Directors (GlobeNewswire)
Sep-15-22 08:00AM	Pasithea Therapeutics Further Strengthens its Scientific Advisory Board with the Appointment of Dr. Merit Cudkowicz (GlobeNewswire)
Sep-12-22 11:53AM	Here's Why We're Not Too Worried About Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn Situation (Simply Wall St.)
Sep-09-22 10:32AM	Pasithea Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Sep-06-22 09:30AM	Investor Group Successful in Request to Call Special Meeting of Stockholders of Pasithea Therapeutics (Business Wire)
Aug-24-22 08:00AM	Investor Group Urges Stockholders of Pasithea Therapeutics to Vote to Call Special Meeting (Business Wire)
Aug-18-22 08:00AM	Pasithea Therapeutics to Present Results of Tolerizing Vaccine Program at Prestigious International Immunotherapy Conference (GlobeNewswire)
Aug-11-22 08:00AM	Pasithea Therapeutics Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy in Relapsing-Remitting Model of Multiple Sclerosis (GlobeNewswire) +6.83%
07:30AM	EXCLUSIVE: Pasithea's Multiple Sclerosis Vaccine Candidate Shows Efficacy In Animal Studies, With Potential In Monkeypox (Benzinga)
Aug-05-22 09:00AM	Investor Group Urges Stockholders of Pasithea Therapeutics Corp. to Call Special Meeting (Business Wire)
Aug-02-22 07:00AM	Pasithea Therapeutics Urges Stockholders to Reject Activist Camac Groups Unjustified Campaign (GlobeNewswire)
Jul-14-22 08:00AM	Pasithea Therapeutics Awarded a Drug Development Research Grant (GlobeNewswire)
Jun-23-22 09:00AM	Investor Group Comments on Pasithea Therapeutics Seemingly Defensive and Dilutive Related-Party Acquisition of Alpha-5 (Business Wire)
08:00AM	Pasithea Therapeutics to Participate in the H.C. Wainwright 1st Annual Mental Health Conference: Neuropsychiatry, Psychedelics and Beyond (GlobeNewswire)
Jun-22-22 08:00AM	Pasithea Therapeutics Acquires Alpha-5 Integrin, LLC (GlobeNewswire)
07:30AM	EXCLUSIVE: Pasithea Expands Its Core Therapeutic Pipeline With This Acquisition (Benzinga)
Apr-14-22 04:15PM	Pasithea Therapeutics to Present at the NobleCon18 Investor Conference 2022 (GlobeNewswire) +9.76%
Apr-05-22 03:57PM	We're Not Worried About Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn (Simply Wall St.)
Mar-30-22 04:15PM	Pasithea Therapeutics Announces Financial and Business Results for the Fourth Quarter and Full Year 2021 and Business Update for 2022 (GlobeNewswire)
Mar-08-22 08:00AM	Pasithea Therapeutics Announces Collaboration with The Glimpse Group (GlobeNewswire) +7.08%
07:30AM	EXCLUSIVE: Glimpse-Pasithea To Co-Develop VR Environments For Patients With Psychiatric Disorders (Benzinga)
Feb-24-22 08:00AM	Pasithea Therapeutics Announces Plans to Open Three New Clinics in the UK by Mid-2022 (GlobeNewswire)
Feb-09-22 08:00AM	Pasithea Therapeutics Strengthens its Scientific Advisory Board with the Appointment of Preeminent Scientist Dr. Daniel Weinberger (GlobeNewswire)
Feb-03-22 08:00AM	Pasithea Therapeutics Initiates New Chemical Entity Drug Development Program in Multiple Sclerosis (GlobeNewswire) -6.40%
Jan-26-22 08:00AM	Pasithea Therapeutics Announces Opening of Mental Health Clinic in Los Angeles and Broadens Focus Beyond Ketamine Treatments (GlobeNewswire)
Dec-23-21 11:35AM	KTTA Stock Alert: 6 Things to Know About Pasithea Therapeutics as Shares Soar Today (InvestorPlace) +36.73%
07:36AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
Dec-21-21 08:00AM	Pasithea Therapeutics Opens Second Ketamine Therapy Clinic in the United Kingdom (GlobeNewswire) +9.72%
Dec-01-21 08:00AM	Pasithea Therapeutics Expands its Mobile Clinics into Florida and Nevada (GlobeNewswire) -8.59%
Nov-29-21 05:45PM	Pasithea Therapeutics Corp. Announces Closing of $30.4 Million Private Placement Priced at a Premium to the Market Under Nasdaq Rules (GlobeNewswire) +5.99%
Nov-24-21 08:52AM	Pasithea Therapeutics Corp. Announces Pricing of a $30.4 Million Private Placement Priced at a Premium to the Market Under Nasdaq Rules (GlobeNewswire) -28.75%
07:34AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
Nov-23-21 11:39AM	5 Top Stock Gainers for Tuesday Climb After Powell Renomination (TheStreet.com) +153.39%
11:31AM	KTTA Stock: The Depression Nasal Spray News That Has Pasithea Therapeutics Investors Ecstatic Today (InvestorPlace)
08:00AM	Pasithea Therapeutics Adds Esketamine Nasal Spray to its Clinic Offerings in the U.K. (GlobeNewswire)
05:02AM	Pasithea Therapeutics Stock Skyrockets On Nasal Spray Approval (Investing.com)
Nov-17-21 08:00AM	Pasithea Therapeutics Launches In-Home Intravenous Ketamine Therapy in Major U.S. Cities, Expanding its International Footprint (GlobeNewswire) -5.18%
07:30AM	EXCLUSIVE: Pasithea Clinics Launches In-Home Intravenous Ketamine Therapy In Major US Cities (Benzinga)
Nov-11-21 08:00AM	Pasithea Therapeutics Collaborates with Renowned Musician and Producer to Create Soundtracks for Ketamine Therapy (GlobeNewswire)
Nov-09-21 08:00AM	Pasithea Therapeutics Corp. Establishes Scientific Advisory Board and Names Dr. Charles B. Nemeroff as Chair (GlobeNewswire)
Oct-27-21 11:40AM	Biotech Companies Are Embracing the Growing Psychedelic Drug Market To Confront a Global Increase in Depression and Anxiety (Benzinga) +9.23%
07:45AM	Pasithea Therapeutics Announces Successful Treatment of First Patients in the UK with Ketamine Infusion Therapy (GlobeNewswire)
07:15AM	EXCLUSIVE: Pasithea Administers First IV Ketamine Infusion Therapy In Depression Patients (Benzinga)
Oct-18-21 01:37PM	Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation (Benzinga) -6.04%
11:07AM	This Company Just Extended its Reach into the United Kingdom by Opening its First Ketamine Therapy Clinic (Benzinga)
Oct-14-21 09:13AM	Pasithea Therapeutics Opens its First Ketamine Therapy Clinic in the United Kingdom (Benzinga) +8.18%
07:15AM	EXCLUSIVE: Pasithea Therapeutics Launches First Ketamine Clinic In The UK (Benzinga)
Oct-11-21 10:08AM	Biotech Company Pasithea Therapeutics Teams Up With Evotec to Aid Mental Health Drug Discovery (Benzinga)
08:20AM	Pasithea Therapeutics Corp. and Evotec SE Enter into Drug Development Agreement (Benzinga)
Oct-05-21 08:37AM	Biotech Company Pasithea Offers Two-Pronged Approach in Psychiatric Treatment (Benzinga)
Oct-04-21 08:00AM	SmallCapsDaily: Pasithea Therapeutics Emerges as a Major Player in the Biotech Industry (Newsfile) -5.92%
Sep-29-21 04:30PM	Pasithea Therapeutics Corp. to Present at the Benzinga Healthcare Small Cap Conference (GlobeNewswire)
Sep-20-21 12:51PM	Psyched: First Active Psychedelics ETF Hits NYSE, Compass Dives Into Novel Molecules, Atai Subsidiary Launches Phase 2a Trial (Benzinga)

Pasithea Therapeutics Corp. is a biotechnology company focuses on the research and discovery of new and treatments for psychiatric and neurological disorders. The company was founded by Yassine Bendiabdallah and Steinman Lawrence J in May, 2020 and is headquartered in Miami Beach, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
STEINMAN LAWRENCE	Director	Jun 02 '23	Buy	0.43	30,000	12,930	1,327,174	Jun 06 09:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KTTA

Pasithea Therapeutics Corp

Upgrade your FINVIZ experience